세계의 스코폴라민 시장 규모 조사 : 제형별, 용도별, 투여 경로별, 유통경로별, 지역별 예측(2022-2032년)

Global Scopolamine Market is valued approximately at USD 0.41 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.30% over the forecast period 2024-2032. Scopolamine, an anticholinergic agent derived from nightshade plants, has long served as a cornerstone treatment for motion sickness and postoperative nausea and vomiting (PONV). As travel volumes rebound globally and the demand for comfort-oriented therapeutics rises, scopolamine's relevance has been renewed, not just among travelers but within hospital systems managing surgical recovery. Widely utilized for its efficacy and rapid onset, scopolamine is increasingly being reformulated across dosage forms-ranging from traditional tablets and transdermal patches to fast-acting injectables-allowing for broader patient access and better symptom resolution.

Growth in the scopolamine market is being steered by several converging drivers. Firstly, the rising volume of surgical procedures worldwide, accompanied by advancements in anesthetic protocols, has triggered an increase in demand for postoperative antiemetics. Secondly, a noticeable uptick in global tourism and cruise ship travel-where motion sickness incidence is notably high-is reinforcing over-the-counter product sales, especially in the transdermal patch segment. Additionally, increasing consumer preference for non-invasive treatment options is pushing manufacturers to innovate in controlled-release topical applications. Nevertheless, the market continues to grapple with clinical limitations such as drowsiness, dry mouth, and contraindications in patients with glaucoma or urinary tract issues, necessitating cautious prescription practices.

To stay competitive, pharmaceutical companies are actively collaborating with research labs and biotech startups to enhance the pharmacokinetic profile of scopolamine. These partnerships aim to introduce longer-lasting, more tolerable delivery systems while expanding into neuroprotective applications for diseases such as Parkinson's and Alzheimer's. Moreover, regulatory approvals for new formulation patents and growing distribution through online channels are opening new commercial pathways. This wave of innovation is particularly favorable for extending market penetration into emerging economies where awareness and diagnosis of motion-related disorders are growing rapidly due to improvements in healthcare infrastructure.

North America currently leads the global scopolamine market, benefiting from high consumer awareness, substantial OTC drug sales, and proactive FDA support for patch-based therapies. Europe ranks as the second-largest regional market, supported by advanced public healthcare systems and rising surgical volumes in countries like Germany, the UK, and France. Meanwhile, Asia Pacific is projected to grow at the fastest CAGR throughout the forecast period, driven by the increasing prevalence of motion sickness in densely populated countries, burgeoning medical tourism, and expanding distribution through e-pharmacies. Latin America and the Middle East & Africa are gradually catching up, bolstered by increasing access to travel medicine and expansion of outpatient surgical care centers.

Major market player included in this report are:

• GlaxoSmithKline plc
• Baxter International Inc.
• Novartis AG
• Mylan N.V.
• Pfizer Inc.
• Perrigo Company plc
• Teva Pharmaceutical Industries Ltd.
• Bausch Health Companies Inc.
• Bayer AG
• Zydus Lifesciences Ltd.
• Upsher-Smith Laboratories LLC
• Boehringer Ingelheim International GmbH
• Sciegen Pharmaceuticals Inc.
• Hikma Pharmaceuticals PLC
• Johnson & Johnson

The detailed segments and sub-segment of the market are explained below:

By Dosage Form

• Transdermal Patches
• Tablets
• Injectables

By Application

• Motion Sickness
• Postoperative Nausea and Vomiting

By Route of Administration

• Topical
• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Scopolamine Market Executive Summary

• 1.1. Global Scopolamine Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Dosage Form
  • 1.3.2. By Application
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Scopolamine Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory Frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Scopolamine Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Rising Volume of Surgical Procedures and Demand for PONV Management
  • 3.1.2. Rebound in Global Tourism and Cruise Travel
  • 3.1.3. Consumer Preference for Non-invasive Controlled-release Therapies
• 3.2. Market Challenges
  • 3.2.1. Anticholinergic Side-effects and Contraindications
  • 3.2.2. Regulatory Constraints on New Formulations
• 3.3. Market Opportunities
  • 3.3.1. Innovation in Long-acting Delivery Systems
  • 3.3.2. Expansion through Online Pharmacies
  • 3.3.3. Penetration into Emerging Healthcare Markets

Chapter 4. Global Scopolamine Market Industry Analysis

• 4.1. Porter's Five Forces Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's Five Forces
  • 4.1.7. Porter's Five Forces Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economic
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunities
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspectives
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Scopolamine Market Size & Forecasts by Dosage Form, 2022-2032

• 5.1. Segment Dashboard
• 5.2. Dosage Form Revenue Trend Analysis, 2022 & 2032 (USD Million)
  • 5.2.1. Transdermal Patches
  • 5.2.2. Tablets
  • 5.2.3. Injectables

Chapter 6. Global Scopolamine Market Size & Forecasts by Application, 2022-2032

• 6.1. Segment Dashboard
• 6.2. Application Revenue Trend Analysis, 2022 & 2032 (USD Million)
  • 6.2.1. Motion Sickness
  • 6.2.2. Postoperative Nausea and Vomiting

Chapter 7. Global Scopolamine Market Size & Forecasts by Region, 2022-2032

• 7.1. North America Scopolamine Market
  • 7.1.1. U.S. Scopolamine Market
    • 7.1.1.1. Dosage Form breakdown, 2022-2032
    • 7.1.1.2. Application breakdown, 2022-2032
  • 7.1.2. Canada Scopolamine Market
• 7.2. Europe Scopolamine Market
  • 7.2.1. UK Scopolamine Market
  • 7.2.2. Germany Scopolamine Market
  • 7.2.3. France Scopolamine Market
  • 7.2.4. Spain Scopolamine Market
  • 7.2.5. Italy Scopolamine Market
  • 7.2.6. Rest of Europe Scopolamine Market
• 7.3. Asia Pacific Scopolamine Market
  • 7.3.1. China Scopolamine Market
  • 7.3.2. India Scopolamine Market
  • 7.3.3. Japan Scopolamine Market
  • 7.3.4. Australia Scopolamine Market
  • 7.3.5. South Korea Scopolamine Market
  • 7.3.6. Rest of Asia Pacific Scopolamine Market
• 7.4. Latin America Scopolamine Market
  • 7.4.1. Brazil Scopolamine Market
  • 7.4.2. Mexico Scopolamine Market
  • 7.4.3. Rest of Latin America Scopolamine Market
• 7.5. Middle East & Africa Scopolamine Market
  • 7.5.1. Saudi Arabia Scopolamine Market
  • 7.5.2. South Africa Scopolamine Market
  • 7.5.3. Rest of Middle East & Africa Scopolamine Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
  • 8.1.1. GlaxoSmithKline plc
  • 8.1.2. Baxter International Inc.
  • 8.1.3. Novartis AG
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. GlaxoSmithKline plc
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Market Strategies
  • 8.3.2. Baxter International Inc.
  • 8.3.3. Novartis AG
  • 8.3.4. Mylan N.V.
  • 8.3.5. Pfizer Inc.
  • 8.3.6. Perrigo Company plc
  • 8.3.7. Teva Pharmaceutical Industries Ltd.
  • 8.3.8. Bausch Health Companies Inc.
  • 8.3.9. Bayer AG
  • 8.3.10. Zydus Lifesciences Ltd.

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes